LinkedIn Profile

Access convoy therapeutics historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:convoytherapeutics 3206428 Mar 23rd, 2018 12:00AM Convoy Therapeutics 74 0.00 Open Pharmaceuticals Mar 23rd, 2017 10:51AM Mar 23rd, 2017 10:51AM BETTER SOLUTIONS, BETTER HEALTH Convoy Therapeutics is a biopharmaceutical company with a product engine disrupting how diseases of the skin are treated. Convoy’s platform technology enables large and small molecules to penetrate and remain localized in the skin. The company has preclinical programs in psoriasis, eczema, acne and pigmentation, and one platform-developed asset being commercialized through partners and a second asset poised internally for clinical development. Convoy is raising its Series A financing to support clinical development of CycloPsorb™, a novel form of cyclosporine that can be used topically for mild and moderate psoriasis. While oral cyclosporine is used for severe psoriasis, its systemic safety profile precludes its use in mild and moderate forms of the disease. The Convoy platform technology allows cyclosporine to penetrate the skin, while avoiding systemic absorption and distribution, allowing the active molecule to treat psoriasis at the site of disease without potential for systemic effects. CycloPsorb, the second asset developed from Convoy’s platform technology, has been cleared by the FDA for expedited development as it uses an approved pharmaceutical in a novel formulation. Convoy expects that early revenue from its first product, coupled with development and commercialization of CycloPsorb, will demonstrate the value of its platform technology and allow for long-term company growth. convoy therapeutics Health Care Equipment & Services
private:convoytherapeutics 3206428 Feb 17th, 2018 12:00AM Convoy Therapeutics 74 0.00 Open Pharmaceuticals Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM BETTER SOLUTIONS, BETTER HEALTH Convoy Therapeutics is a biopharmaceutical company with a product engine disrupting how diseases of the skin are treated. Convoy’s platform technology enables large and small molecules to penetrate and remain localized in the skin. The company has preclinical programs in psoriasis, eczema, acne and pigmentation, and one platform-developed asset being commercialized through partners and a second asset poised internally for clinical development. Convoy is raising its Series A financing to support clinical development of CycloPsorb™, a novel form of cyclosporine that can be used topically for mild and moderate psoriasis. While oral cyclosporine is used for severe psoriasis, its systemic safety profile precludes its use in mild and moderate forms of the disease. The Convoy platform technology allows cyclosporine to penetrate the skin, while avoiding systemic absorption and distribution, allowing the active molecule to treat psoriasis at the site of disease without potential for systemic effects. CycloPsorb, the second asset developed from Convoy’s platform technology, has been cleared by the FDA for expedited development as it uses an approved pharmaceutical in a novel formulation. Convoy expects that early revenue from its first product, coupled with development and commercialization of CycloPsorb, will demonstrate the value of its platform technology and allow for long-term company growth. convoy therapeutics Health Care Equipment & Services
private:convoytherapeutics 3206428 Feb 16th, 2018 12:00AM Convoy Therapeutics 74 0.00 Open Pharmaceuticals Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM BETTER SOLUTIONS, BETTER HEALTH Convoy Therapeutics is a biopharmaceutical company with a product engine disrupting how diseases of the skin are treated. Convoy’s platform technology enables large and small molecules to penetrate and remain localized in the skin. The company has preclinical programs in psoriasis, eczema, acne and pigmentation, and one platform-developed asset being commercialized through partners and a second asset poised internally for clinical development. Convoy is raising its Series A financing to support clinical development of CycloPsorb™, a novel form of cyclosporine that can be used topically for mild and moderate psoriasis. While oral cyclosporine is used for severe psoriasis, its systemic safety profile precludes its use in mild and moderate forms of the disease. The Convoy platform technology allows cyclosporine to penetrate the skin, while avoiding systemic absorption and distribution, allowing the active molecule to treat psoriasis at the site of disease without potential for systemic effects. CycloPsorb, the second asset developed from Convoy’s platform technology, has been cleared by the FDA for expedited development as it uses an approved pharmaceutical in a novel formulation. Convoy expects that early revenue from its first product, coupled with development and commercialization of CycloPsorb, will demonstrate the value of its platform technology and allow for long-term company growth. convoy therapeutics Health Care Equipment & Services
private:convoytherapeutics 3206428 Feb 15th, 2018 12:00AM Convoy Therapeutics 74 0.00 Open Pharmaceuticals Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM BETTER SOLUTIONS, BETTER HEALTH Convoy Therapeutics is a biopharmaceutical company with a product engine disrupting how diseases of the skin are treated. Convoy’s platform technology enables large and small molecules to penetrate and remain localized in the skin. The company has preclinical programs in psoriasis, eczema, acne and pigmentation, and one platform-developed asset being commercialized through partners and a second asset poised internally for clinical development. Convoy is raising its Series A financing to support clinical development of CycloPsorb™, a novel form of cyclosporine that can be used topically for mild and moderate psoriasis. While oral cyclosporine is used for severe psoriasis, its systemic safety profile precludes its use in mild and moderate forms of the disease. The Convoy platform technology allows cyclosporine to penetrate the skin, while avoiding systemic absorption and distribution, allowing the active molecule to treat psoriasis at the site of disease without potential for systemic effects. CycloPsorb, the second asset developed from Convoy’s platform technology, has been cleared by the FDA for expedited development as it uses an approved pharmaceutical in a novel formulation. Convoy expects that early revenue from its first product, coupled with development and commercialization of CycloPsorb, will demonstrate the value of its platform technology and allow for long-term company growth. convoy therapeutics Health Care Equipment & Services
private:convoytherapeutics 3206428 Feb 14th, 2018 12:00AM Convoy Therapeutics 74 0.00 Open Pharmaceuticals Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM BETTER SOLUTIONS, BETTER HEALTH Convoy Therapeutics is a biopharmaceutical company with a product engine disrupting how diseases of the skin are treated. Convoy’s platform technology enables large and small molecules to penetrate and remain localized in the skin. The company has preclinical programs in psoriasis, eczema, acne and pigmentation, and one platform-developed asset being commercialized through partners and a second asset poised internally for clinical development. Convoy is raising its Series A financing to support clinical development of CycloPsorb™, a novel form of cyclosporine that can be used topically for mild and moderate psoriasis. While oral cyclosporine is used for severe psoriasis, its systemic safety profile precludes its use in mild and moderate forms of the disease. The Convoy platform technology allows cyclosporine to penetrate the skin, while avoiding systemic absorption and distribution, allowing the active molecule to treat psoriasis at the site of disease without potential for systemic effects. CycloPsorb, the second asset developed from Convoy’s platform technology, has been cleared by the FDA for expedited development as it uses an approved pharmaceutical in a novel formulation. Convoy expects that early revenue from its first product, coupled with development and commercialization of CycloPsorb, will demonstrate the value of its platform technology and allow for long-term company growth. convoy therapeutics Health Care Equipment & Services
private:convoytherapeutics 3206428 Feb 13th, 2018 12:00AM Convoy Therapeutics 74 0.00 Open Pharmaceuticals Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM BETTER SOLUTIONS, BETTER HEALTH Convoy Therapeutics is a biopharmaceutical company with a product engine disrupting how diseases of the skin are treated. Convoy’s platform technology enables large and small molecules to penetrate and remain localized in the skin. The company has preclinical programs in psoriasis, eczema, acne and pigmentation, and one platform-developed asset being commercialized through partners and a second asset poised internally for clinical development. Convoy is raising its Series A financing to support clinical development of CycloPsorb™, a novel form of cyclosporine that can be used topically for mild and moderate psoriasis. While oral cyclosporine is used for severe psoriasis, its systemic safety profile precludes its use in mild and moderate forms of the disease. The Convoy platform technology allows cyclosporine to penetrate the skin, while avoiding systemic absorption and distribution, allowing the active molecule to treat psoriasis at the site of disease without potential for systemic effects. CycloPsorb, the second asset developed from Convoy’s platform technology, has been cleared by the FDA for expedited development as it uses an approved pharmaceutical in a novel formulation. Convoy expects that early revenue from its first product, coupled with development and commercialization of CycloPsorb, will demonstrate the value of its platform technology and allow for long-term company growth. convoy therapeutics Health Care Equipment & Services
private:convoytherapeutics 3206428 Feb 12th, 2018 12:00AM Convoy Therapeutics 74 0.00 Open Pharmaceuticals Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM BETTER SOLUTIONS, BETTER HEALTH Convoy Therapeutics is a biopharmaceutical company with a product engine disrupting how diseases of the skin are treated. Convoy’s platform technology enables large and small molecules to penetrate and remain localized in the skin. The company has preclinical programs in psoriasis, eczema, acne and pigmentation, and one platform-developed asset being commercialized through partners and a second asset poised internally for clinical development. Convoy is raising its Series A financing to support clinical development of CycloPsorb™, a novel form of cyclosporine that can be used topically for mild and moderate psoriasis. While oral cyclosporine is used for severe psoriasis, its systemic safety profile precludes its use in mild and moderate forms of the disease. The Convoy platform technology allows cyclosporine to penetrate the skin, while avoiding systemic absorption and distribution, allowing the active molecule to treat psoriasis at the site of disease without potential for systemic effects. CycloPsorb, the second asset developed from Convoy’s platform technology, has been cleared by the FDA for expedited development as it uses an approved pharmaceutical in a novel formulation. Convoy expects that early revenue from its first product, coupled with development and commercialization of CycloPsorb, will demonstrate the value of its platform technology and allow for long-term company growth. convoy therapeutics Health Care Equipment & Services
private:convoytherapeutics 3206428 Feb 11th, 2018 12:00AM Convoy Therapeutics 74 0.00 Open Pharmaceuticals Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM BETTER SOLUTIONS, BETTER HEALTH Convoy Therapeutics is a biopharmaceutical company with a product engine disrupting how diseases of the skin are treated. Convoy’s platform technology enables large and small molecules to penetrate and remain localized in the skin. The company has preclinical programs in psoriasis, eczema, acne and pigmentation, and one platform-developed asset being commercialized through partners and a second asset poised internally for clinical development. Convoy is raising its Series A financing to support clinical development of CycloPsorb™, a novel form of cyclosporine that can be used topically for mild and moderate psoriasis. While oral cyclosporine is used for severe psoriasis, its systemic safety profile precludes its use in mild and moderate forms of the disease. The Convoy platform technology allows cyclosporine to penetrate the skin, while avoiding systemic absorption and distribution, allowing the active molecule to treat psoriasis at the site of disease without potential for systemic effects. CycloPsorb, the second asset developed from Convoy’s platform technology, has been cleared by the FDA for expedited development as it uses an approved pharmaceutical in a novel formulation. Convoy expects that early revenue from its first product, coupled with development and commercialization of CycloPsorb, will demonstrate the value of its platform technology and allow for long-term company growth. convoy therapeutics Health Care Equipment & Services
private:convoytherapeutics 3206428 Feb 10th, 2018 12:00AM Convoy Therapeutics 74 0.00 Open Pharmaceuticals Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM BETTER SOLUTIONS, BETTER HEALTH Convoy Therapeutics is a biopharmaceutical company with a product engine disrupting how diseases of the skin are treated. Convoy’s platform technology enables large and small molecules to penetrate and remain localized in the skin. The company has preclinical programs in psoriasis, eczema, acne and pigmentation, and one platform-developed asset being commercialized through partners and a second asset poised internally for clinical development. Convoy is raising its Series A financing to support clinical development of CycloPsorb™, a novel form of cyclosporine that can be used topically for mild and moderate psoriasis. While oral cyclosporine is used for severe psoriasis, its systemic safety profile precludes its use in mild and moderate forms of the disease. The Convoy platform technology allows cyclosporine to penetrate the skin, while avoiding systemic absorption and distribution, allowing the active molecule to treat psoriasis at the site of disease without potential for systemic effects. CycloPsorb, the second asset developed from Convoy’s platform technology, has been cleared by the FDA for expedited development as it uses an approved pharmaceutical in a novel formulation. Convoy expects that early revenue from its first product, coupled with development and commercialization of CycloPsorb, will demonstrate the value of its platform technology and allow for long-term company growth. convoy therapeutics Health Care Equipment & Services
private:convoytherapeutics 3206428 Feb 9th, 2018 12:00AM Convoy Therapeutics 74 0.00 Open Pharmaceuticals Feb 9th, 2017 08:57AM Feb 9th, 2017 08:57AM BETTER SOLUTIONS, BETTER HEALTH Convoy Therapeutics is a biopharmaceutical company with a product engine disrupting how diseases of the skin are treated. Convoy’s platform technology enables large and small molecules to penetrate and remain localized in the skin. The company has preclinical programs in psoriasis, eczema, acne and pigmentation, and one platform-developed asset being commercialized through partners and a second asset poised internally for clinical development. Convoy is raising its Series A financing to support clinical development of CycloPsorb™, a novel form of cyclosporine that can be used topically for mild and moderate psoriasis. While oral cyclosporine is used for severe psoriasis, its systemic safety profile precludes its use in mild and moderate forms of the disease. The Convoy platform technology allows cyclosporine to penetrate the skin, while avoiding systemic absorption and distribution, allowing the active molecule to treat psoriasis at the site of disease without potential for systemic effects. CycloPsorb, the second asset developed from Convoy’s platform technology, has been cleared by the FDA for expedited development as it uses an approved pharmaceutical in a novel formulation. Convoy expects that early revenue from its first product, coupled with development and commercialization of CycloPsorb, will demonstrate the value of its platform technology and allow for long-term company growth. convoy therapeutics Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.